[1]程 林.重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究[J].医学信息,2018,(08):126-127,133.[doi:10.3969/j.issn.1006-1959.2018.08.042]
 CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,(08):126-127,133.[doi:10.3969/j.issn.1006-1959.2018.08.042]
点击复制

重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年08期
页码:
126-127,133
栏目:
药物与临床
出版日期:
2018-04-15

文章信息/Info

Title:
Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure
文章编号:
1006-1959(2018)08-0126-03
作者:
程 林
黑龙江省佳木斯市中心医院心内一科,黑龙江 佳木斯 154002
Author(s):
CHENG Lin
Department of Heart,Subject One,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China
关键词:
重组人脑利钠肽重症急性心肌炎心力衰竭
Keywords:
Key words:Recombinant human brain natriuretic peptideSevere acute myocarditisHeart failure
分类号:
R542.21
DOI:
10.3969/j.issn.1006-1959.2018.08.042
文献标志码:
A
摘要:
目的 研究重组人脑利钠肽应用于重症急性心肌炎伴心力衰竭患者在临床治疗的效果。方法 选取我院2014年1月~2017年6月收治的98例急性心肌炎合并心力衰竭患者,并随机均分为实验组和对照组,每组49例。对照组行常规的抗心力衰竭治疗,实验组在对照组的基础上行静脉泵入重组人脑利钠肽。72 h后测定两组患者用药前后血清N末端脑钠肽前体水平、左室射血分数和Supper-Score的评分。结果 72 h后两组患者N末端脑钠肽前提水平均:用药前>对照组>实验组,左室射血分数:实验组>对照组>用药前,差异存在统计学意义(P<0.05),两组患者用药前N末端脑钠肽前体水平、左室射血分数的差异,无统计学意义(P>0.05)。结论 重组人脑利钠肽应用于重症急性心肌炎伴心力衰竭患者的疗效显著,可推广应用。
Abstract:
Abstract:Objective To study the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of severe acute myocarditis with heart failure.Methods 98 patients with acute myocarditis complicated with heart failure from January 2014 to June 2017 were randomly divided into experimental group and control group with 49 cases in each group.The control group was treated with routine anti-heart failure therapy,on the basis of the control group,the experimental group was injected with recombinant human brain natriuretic peptide.72 h on the basis of the control group.The serum N terminal brain natriuretic peptide level,the left ventricular ejection fraction and the score of Supper-Score were measured before and after the use of the two groups.Results After 72 h,the N terminal brain natriuretic peptide precondition water was mean:before medication>control group>experimental group,left ventricular ejection fraction:experimental group>control group>before medication,the difference was statistically significant(P<0.05).The difference of the level of brain natriuretic precursor and left ventricular ejection fraction in the two groups before use was not statistically significant(P>0.05).Conclusion Recombinant human brain natriuretic peptide is effective in the treatment of severe acute myocarditis with heart failure,and it can be widely applied.

参考文献/References:

[1]陆明,黄好华,罗建春,等.重组人脑利钠肽对中国人群急性心力衰竭影响的Meta分析[J].中国循证医学杂志,2010,10(5):570-577.
[2]边圆.急性心衰早期预警评分模型的建立与应用[D].山东大学,2015.
[3]夏向南,缪海雄,陈华,等.脑利钠肽对老年心力衰竭预后的价值探讨(附62例分析)[J].福建医药杂志,2008,30(2):8-10.
[4]赵鑫峰,刘佳云,张美兰.冻干重组人脑利钠肽治疗充血性心力衰竭临床疗效分析[J].山西医药杂志,2014,43(24):2292-2924.
[5]谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-226.
[6]罗晓丽,邓仁生,申源生.重组人脑利钠肽治疗急性重症心肌炎伴心力衰竭患者的临床观察[J].中国医药指南,2013,11(24):250-251.

更新日期/Last Update: 2018-04-15